POMBILITI ATGA 105 mg/1
cipaglucosidase alfa-atga · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · AMICUS THERAPEUTICS US, LLC
Pombiliti Atga (cipaglucosidase alfa-atga) is an intravenous injection used to treat Pompe disease, a rare genetic disorder that affects muscle function. It works by helping the body break down a type of sugar that accumulates in muscles and other tissues.
Key Facts
- Brand Name
- POMBILITI ATGA
- Generic Name
- cipaglucosidase alfa-atga
- NDC Code (Product)
71904-200- Manufacturer
- AMICUS THERAPEUTICS US, LLC
- Strength
- 105 mg/1
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761204
- Marketing Start
- 10/11/2023
Recall History
No Recall HistoryFrequently Asked Questions
What is POMBILITI ATGA used for?
Pombiliti Atga (cipaglucosidase alfa-atga) is an intravenous injection used to treat Pompe disease, a rare genetic disorder that affects muscle function. It works by helping the body break down a type of sugar that accumulates in muscles and other tissues.
Is POMBILITI ATGA a controlled substance?
POMBILITI ATGA is not classified as a controlled substance by the DEA.
What is the generic name for POMBILITI ATGA?
The generic name for POMBILITI ATGA is cipaglucosidase alfa-atga. There are no other listed brand versions of cipaglucosidase alfa-atga.
What is the NDC code for POMBILITI ATGA 105 mg/1?
The NDC (National Drug Code) for POMBILITI ATGA 105 mg/1 is 71904-200, listed by AMICUS THERAPEUTICS US, LLC.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)